In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines

被引:13
|
作者
Kumar, Yogesh [1 ]
Mazurek, Sybille [2 ,3 ]
Yang, Shiyu [1 ]
Failing, Klaus [4 ]
Winslet, Marc [1 ]
Fuller, Barry [1 ]
Davidson, Brian R. [1 ]
机构
[1] UCL, Royal Free & Univ Coll Med Sch, Univ Dept Surg, London NW3 2QG, England
[2] Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, D-35392 Giessen, Germany
[3] ScheBo Biotech AG, D-35394 Giessen, Germany
[4] Univ Giessen, Fac Vet, Unit Biomath, D-35392 Giessen, Germany
关键词
pyruvate kinase M2; Tumour M2-PK; Tumour microenvironment; Pancreatic cancer; PYRUVATE-KINASE; MARKER; CARCINOMA; APOPTOSIS; GLUCOSE; M2; GLYCOLYSIS; METABOLISM; EXPRESSION; DIAGNOSIS;
D O I
10.1007/s13277-009-0010-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In tumour cells, the tetramer/dimer ratio of the pyruvate kinase isoenzyme type M2 (M2-PK) determines whether glucose carbons are degraded to lactate with production of energy (tetrameric form) or are channelled into synthetic processes (dimeric form). The influence of different tumour microenvironment conditions on the tetramer/dimer ratio of M2-PK and cell doublings were investigated in a non-metastatic and metastatic pancreatic cancer cell line. The metastatic Colo357 cells contained about fourfold more M2-PK protein and about 3.5-fold more dimeric M2-PK than the non-metastatic Panc-1 cells. In Colo357 cells hypoxia, glucose starvation as well as acidification induced an increase of the dimeric form of M2-PK, whereas in Panc-1 cells no effect on M2-PK was observed. Under hypoxia in Colo357 cells, the dimerization and inactivation of M2-PK results in an inhibition of cell proliferation, whereas under glucose starvation and acidification the dimerization of M2-PK allowed further cell doublings. M2-PK expression and the quaternary structure of M2-PK are influenced by the tumour metastatic potential. The quaternary structure of M2-PK may be differently affected by hypoxia, glucose starvation and acidification with severe consequences on cell doublings.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 50 条
  • [21] Evaluation of serum and pleural levels tumor M2-pyruvate kinase in lung cancer patients with pleural effusion
    Tiantian Zhang
    Wei Liu
    Li Li
    Zou Jue
    Chunhua Xu
    BMC Pulmonary Medicine, 22
  • [22] Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis
    Li, He
    Xu, Huiyu
    Xing, Rui
    Pan, Yuanming
    Li, Wenmei
    Cui, Jiantao
    Lu, Youyong
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [23] The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study
    Alhadi, Shahidah Che
    Zain, Wan Zainira Wan
    Zahari, Zalina
    Hashim, Mohd Nizam Md
    Abd Aziz, Syed Hassan Syed
    Zakaria, Zaidi
    Wong, Michael Pak-Kai
    Zakaria, Andee Dzulkarnaen
    ANNALS OF COLOPROCTOLOGY, 2020, 36 (06) : 409 - 414
  • [24] A comprehensive analysis of the pyruvate kinase M1/2 (PKM) in human cancer
    Xue, Shuaishuai
    Luo, Ziyi
    Mao, Yangqi
    Liu, Siyuan
    GENE, 2025, 937
  • [25] The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer
    Ogawa, Hisataka
    Nagano, Hiroaki
    Konno, Masamitsu
    Eguchi, Hidetoshi
    Koseki, Jun
    Kawamoto, Koichi
    Nishida, Naohiro
    Colvin, Hugh
    Tomokuni, Akira
    Tomimaru, Yoshito
    Hama, Naoki
    Wada, Hiroshi
    Marubashi, Shigeru
    Kobayashi, Shogo
    Mori, Masaki
    Doki, Yuichiro
    Ishii, Hideshi
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (03) : 563 - 571
  • [26] Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
    Chen, J.
    Xie, J.
    Jiang, Z.
    Wang, B.
    Wang, Y.
    Hu, X.
    ONCOGENE, 2011, 30 (42) : 4297 - 4306
  • [27] Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture
    Okada, Gensaku
    Watanabe, Hiroyuki
    Ohtsubo, Koushiro
    Mouri, Hisatsugu
    Yamaguchi, Yasushi
    Motoo, Yoshiharu
    Sawabu, Norio
    CELL BIOLOGY INTERNATIONAL, 2012, 36 (06) : 545 - 553
  • [28] Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer
    Dhar, Dipok Kumar
    Damink, Steven W. M. Olde
    Brindley, James Hal
    Godfrey, Andrew
    Chapman, Michael H.
    Sandanayake, Neomal S.
    Andreola, Fausto
    Mazurek, Sybille
    Hasan, Tayyaba
    Malago, Massimo
    Pereira, Stephen P.
    CANCER, 2013, 119 (03) : 575 - 585
  • [29] Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells
    Kim, Dong Joon
    Park, Young Soo
    Kang, Min Gu
    You, Yeon-Mi
    Jung, Yuri
    Koo, Han
    Kim, Jung-Ae
    Kim, Mi-Ju
    Hong, Seung-Mo
    Lee, Kyong Bun
    Jang, Ja-June
    Park, Kyung Chan
    Yeom, Young Ii
    EXPERIMENTAL CELL RESEARCH, 2015, 336 (01) : 119 - 129
  • [30] Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23
    Wei, Yao
    Wang, Dong
    Jin, Fangfang
    Bian, Zhen
    Li, Limin
    Liang, Hongwei
    Li, Mingzhen
    Shi, Lei
    Pan, Chaoyun
    Zhu, Dihan
    Chen, Xi
    Hu, Gang
    Liu, Yuan
    Zhang, Chen-Yu
    Zen, Ke
    NATURE COMMUNICATIONS, 2017, 8